PHVS · NASDAQ · Biotechnology

Pharvaris (PHVS)

Develops oral deucrictibant formulations to treat and prevent hereditary angioedema attacks.

$35.20
After hours+0.01 (+0.03%)
At close$35.19(−2.30%)